


Express Mail No.: EV463104507US
Date of Deposit: September 29, 2005

Page 1 of 1
Attorney Docket No.: 26505-513 (RIB-007)



Please type a plus sign (+) in this box



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/671,326
	Filing Date	September 25, 2003
	First Named Inventor	Wang
	Group Art Unit	1626
	Examiner Name	Nyeemah Grazier
	Attorney Docket Number	26505-513 (RIB-007)

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
------------------	-------------	-----------------------------	------------	-------------------------------------	-------	--------------	-------------------------------

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
------------------	-------------	-----------------------------------	-------------------	-------------------------------------	-------	--------------	----------------------------------

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
MB	B50	WO 02/081470 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	10/17/02	
MB	B51	WO 03/035648 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	05/01/03	
MB	B52	WO 03/072575 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	09/04/03	
MB	B53	WO 2004/056817 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	07/08/04	
MB	B54	WO 2004/056818 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	07/08/04	
MB	B55	WO 2004/078770 A1	RIB-X PHARMACEUTICALS, INC.	09/16/04	
MB	B56	WO 2005/042554 A1	RIB-X PHARMACEUTICALS, INC.	05/12/05	
MB	B57	WO 2005/049632 A1	RIB-X PHARMACEUTICALS, INC.	06/02/05	
MB	B58	WO 2005/085266 A2	RIB-X PHARMACEUTICALS, INC.	09/15/05	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
MB	C18	Gregory et al. <i>J. Med. Chem.</i> , 32:1673-1681 (1989)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	11/07/05
-------------------------------	--	----------------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.:

Date of Deposit:

Page 1 of 2

Attorney Docket No.: 26505-513 (RIB-007)

Please type a plus sign (+) in this box



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.







Approved for use through 9/30/00. OMB 0631-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Modified Form 1448/PTO				Application Number		10/671,326	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date		September 25, 2003	
				First Named Inventor		Wang	
				Group Art Unit		1828	
				Examiner Name		Nysemah Grazier	
				Attorney Docket Number		26505-513 (RIB-007)	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate
NG	A42	5,658,888	08-19-97	Koga et al.	514	29	10-19-94
NG	A44	6,878,691 B2	04-12-05	Or et al.	514	29	05-05-03
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate
NG	A43	2004/0157787 A1	08-12-04	Or et al.	514	28	11-19-03
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
NG	B59	WO 99/64416	ZENECA LIMITED GB	12-16-99			
NG	B60	WO 99/64417	ZENECA LIMITED GB	12-16-99			
NG	B61	WO 00/40589	PLIVA, FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO	07-13-00			
NG	B62	WO 01/40238 A2	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	08-07-01			
NG	B63	WO 02/051855 A2	KOSAN BIOSCIENCES, INC	07-04-02			
NG	B64	WO 02/080841 A2	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	10-17-02			
NG	B65	WO 02/081468 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	10-17-02			
NG	B66	WO 02/081469 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	10-17-02			
NG	B67	WO 02/096890 A2	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	12-05-02			
NG	B68	WO 02/096918 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	12-03-02			
NG	B69	WO 2004/013153 A2	ZAMBON GROUP S.P.A.	12-12-04			

12/1/05

Express Mail No.:
Date of Deposit:

Page 2 of 2
Attorney Docket No.: 26505-513 (RIB-007)

	B70	WO	2004/048392 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	08-10-04		
	B71	WO	2004/056819 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	07-08-04		
	B72	EP	0643068 B1	CHUGAI SEIYAKU KABUSHIKI KAISHA TOKYO 115 JP	08-19-98		
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C19	Jones, P.H., and Powley, E.K., "Chemical Modifications of Erythromycin Antibiotics. I. 3'-De(dimethylamino)erythromycin A and B," J. Org. Chem., 33:665-670 (1968).					
	C20	Stanmark, Heather G., et al., "Biomimetic Synthesis of Macrolide/Ketolide Metabolites through a Selective N-Demethylation Reaction," J. Org. Chem., 65:3876-3876 (2000).					
	C21	Liang, Chang-Hsing, et al., "Synthesis and Biological Activity of New 5-O-Sugar Modified Ketolide and 2-Fluoro-Ketolide Antibiotics," Bioorganic & Medicinal Chem. Letters, 15:1307-1310 (2005).					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	12/01/05
-----------------------	---	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.